

Resource Summary Report

Generated by PRECISE-TBI on Aug 3, 2026

Juvenile Diabetes Research Foundation

RRID:SCR_001522

Type: Tool

Proper Citation

Juvenile Diabetes Research Foundation (RRID:SCR_001522)

Resource Information

URL: <http://jdrf.org/>

Proper Citation: Juvenile Diabetes Research Foundation (RRID:SCR_001522)

Description: Global funder of type 1 diabetes (T1D) research that aims to progressively remove the impact of T1D from people's lives until a world without T1D is achieved. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. More than 80 percent of JDRF's expenditures directly support research and research-related education. In 2012 Forbes magazine named JDRF one of its five All-Star charities, citing the organization's efficiency and effectiveness. The organization awards research grants for laboratory and clinical investigations and sponsors a variety of career development and research training programs for new and established investigators. JDRF also sponsors international workshops and conferences for biomedical researchers. Individual chapters offer support groups and other activities for families affected by diabetes.

Abbreviations: JDRF

Synonyms: JDRF International, Juvenile Diabetes Research Foundation International

Resource Type: institution

Keywords: treatment, prevention, cure, research, education

Related Condition: Type 1 diabetes, Diabetes

Availability: Free, Freely available

Resource Name: Juvenile Diabetes Research Foundation

Resource ID: SCR_001522

Alternate IDs: grid.429307.b, nlx_152841, Crossref funder ID: 100008871, Wikidata: Q6107958, ISNI: 0000 0004 0575 6413

Alternate URLs: <https://ror.org/00vqxjy61>

Record Creation Time: 20220129T080208+0000

Record Last Update: 20260801T190153+0000

Ratings and Alerts

No rating or validation information has been found for Juvenile Diabetes Research Foundation.

No alerts have been found for Juvenile Diabetes Research Foundation.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 64 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Peltonen EJ, et al. (2023) What is the role of puberty in the development of islet autoimmunity and progression to type 1 diabetes? European journal of epidemiology, 38(6), 689.

Lord SM, et al. (2023) Testing a new platform to screen disease-modifying therapy in type 1 diabetes. PloS one, 18(12), e0293268.

Guareschi S, et al. (2023) The positive impact on translational research of Fondazione italiana di ricerca per la Sclerosi Laterale Amiotrofica (AriSLA), a non-profit foundation focused on amyotrophic lateral sclerosis. Convergence of ex-ante evaluation and ex-post outcomes when goals are set upfront. Frontiers in research metrics and analytics, 8, 1067981.

Zaidi SMA, et al. (2021) Multi-step ahead predictive model for blood glucose concentrations of type-1 diabetic patients. Scientific reports, 11(1), 24332.

Syrjälä E, et al. (2021) Determining the timing of pubertal onset via a multicohort analysis of growth. PloS one, 16(11), e0260137.

De Paep DL, et al. (2021) Lower beta cell yield from donor pancreases after controlled circulatory death prevented by shortening acirculatory warm ischemia time and by using IGL-1 cold preservation solution. PloS one, 16(5), e0251055.

Dwulet JM, et al. (2021) Small subpopulations of β -cells do not drive islet oscillatory $[Ca^{2+}]$ dynamics via gap junction communication. *PLoS computational biology*, 17(5), e1008948.

Mastracci TL, et al. (2020) Hypusinated eIF5A is expressed in the pancreas and spleen of individuals with type 1 and type 2 diabetes. *PloS one*, 15(3), e0230627.

Lau H, et al. (2020) Dose-dependent effects of necrostatin-1 supplementation to tissue culture media of young porcine islets. *PloS one*, 15(12), e0243506.

Heile M, et al. (2020) Automated Insulin Delivery: Easy Enough to Use in Primary Care? *Clinical diabetes* : a publication of the American Diabetes Association, 38(5), 474.

Vazquez-Mateo C, et al. (2019) Combining anti-IL-7R α antibodies with autoantigen-specific immunotherapy enhances non-specific cytokine production but fails to prevent Type 1 Diabetes. *PloS one*, 14(3), e0214379.

Braitsch CM, et al. (2019) LATS1/2 suppress NF κ B and aberrant EMT initiation to permit pancreatic progenitor differentiation. *PLoS biology*, 17(7), e3000382.

Scarr D, et al. (2018) Validity of a point-of-care nerve conduction device for polyneuropathy identification in older adults with diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. *PloS one*, 13(4), e0196647.

Simeonovic CJ, et al. (2018) Loss of intra-islet heparan sulfate is a highly sensitive marker of type 1 diabetes progression in humans. *PloS one*, 13(2), e0191360.

Groot Nibbelink M, et al. (2018) An important step towards a prevascularized islet microencapsulation device: in vivo prevascularization by combination of mesenchymal stem cells on micropatterned membranes. *Journal of materials science. Materials in medicine*, 29(11), 174.

Costa OR, et al. (2018) An analytical comparison of three immunoassay platforms for subpicomolar detection of protein biomarker GAD65. *PloS one*, 13(3), e0193670.

Jaakkola MK, et al. (2018) PASI: A novel pathway method to identify delicate group effects. *PloS one*, 13(7), e0199991.

Singh H, et al. (2017) Type 1 Diabetes: Urinary Proteomics and Protein Network Analysis Support Perturbation of Lysosomal Function. *Theranostics*, 7(10), 2704.

Thornley TB, et al. (2016) Contrasting Roles of Islet Resident Immunoregulatory Macrophages and Dendritic Cells in Experimental Autoimmune Type 1 Diabetes. *PloS one*, 11(3), e0150792.

Kodama K, et al. (2016) Expression-Based Genome-Wide Association Study Links Vitamin D-Binding Protein With Autoantigenicity in Type 1 Diabetes. *Diabetes*, 65(5), 1341.